Format
Sort by

Send to

Choose Destination

Search results

Items: 3

1.

Measuring Circulating Complement Activation Products in Myeloperoxidase- and Proteinase 3-Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.

Wu EY, McInnis EA, Boyer-Suavet S, Mendoza CE, Aybar LT, Kennedy KB, Poulton CJ, Henderson CD, Hu Y, Hogan SL, Hu P, Xiao H, Nachman PH, Jennette JC, Falk RJ, Bunch DO.

Arthritis Rheumatol. 2019 Jun 19. doi: 10.1002/art.41011. [Epub ahead of print]

PMID:
31215772
2.

Rituximab bioavailability in primary membranous nephropathy.

Boyer-Suavet S, Andreani M, Cremoni M, Brglez V, Benzaken S, Bernard G, Nachman P, Esnault V, Seitz-Polski B.

Nephrol Dial Transplant. 2019 Mar 30. pii: gfz041. doi: 10.1093/ndt/gfz041. [Epub ahead of print] No abstract available.

PMID:
30929012
3.

Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy.

Thompson A, Carroll K, A Inker L, Floege J, Perkovic V, Boyer-Suavet S, W Major R, I Schimpf J, Barratt J, Cattran DC, S Gillespie B, Kausz A, W Mercer A, Reich HN, H Rovin B, West M, Nachman PH.

Clin J Am Soc Nephrol. 2019 Mar 7;14(3):469-481. doi: 10.2215/CJN.08600718. Epub 2019 Jan 11.

PMID:
30635299

Supplemental Content

Loading ...
Support Center